Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ormation unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a corection or anountement arross at meb-2/a	
Application Number	NOT YET ASSIGNED
Filing Date	SEPTEMBER 5, 2003
First Named Inventor	BATTISTA, et al
Group Art Unit	NOT YET ASSIGNED
Examiner Name	NOT YET ASSIGNED
Attorney Docket Number	PRD-0039-USA-NP

			0 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	U.S. PATENT DOCUMENTS		
Examiner Cite Initials No.1		U.S. Patent Document			Date of Publication	Pages, Columns, Lines,
	Kind Code ⁴ Number (if known)		Name of Patentee or Applicant of Cited Document	of Cited Document	where relevant passages or relevant figures appear	
P		3,238,216		Paul Adriaan Jan Janssen	03-01-1966	
RO		3,839,340		Scharpf	10-01-1974	
PD		4,329,353	A	Stokbroekx et al	05-11-1982	
76		5,739,336	А	Weinhardt et al	04-14-1998	
βo		6,043,366	А	Adam et al	03-28-2000	
p		6,060,482	A	Heine et al	05-09-2000	
R	<u> </u>	6,071,925	A	Adam et al	06-06-2000	
مر	-	6,262,066	B1	Tulshian et al	07-17-2001	
90		6,277,991	B1	Hohlweg et al	08-21-2001	
R		2003/0109539	A1	Jordan et al	06-12-2003	

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document Name of Patentee or passages or relevant T٥ Examiner mm-dd-yyyy Applicant of Cited Document figures appear Initials KindCode⁵ Office³ Number⁴ No.1 06-09-1999 F Hoffman-LaRoche AG В1 Ю EΡ 921,125 ΕP 997,464 A1 Pfizer Inc. 05-03-2000 22 Banyu Pharmaceutical Co., Ltd. 06-20-2000 2000-W 169,476 93/12789 Beth Israel Hospital 07-08-1993 wo A1 03-16-1995 A1 Scios Nova Inc. WO 95/07294 10 wo 99/59997 A1 Novo Nordisk A/S 11-25-1999 02-10-2000 00/06545 A1 Schering Corporation WO 02-01-2001 01/07050 A1 Schering Corporation wo 05-25-2001 01/36418 L Novo Nordisk A/S wo A1 P 06-07-2001 01/39723 Euroceltique, S.A. wo 12-13-2001 Ø 01/94346 V F. Hoffmann-LaRoche AG **A1** wo 02/83673 Ortho-McNeil Pharmaceutical, Inc. 10-24-2002

Examiner Signature	Koerar	Date . Considered	9/1/05
	the state of the s	with MDED 600. Drow line the	ough citation iffoot b conformance

*EXAMINER: Initial if reference considered, whether or not citation is in conforman and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter Tongue clauton designation himber, 2 see statistics of the serior of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

Sheet 2 of 2

b conscension and missis a displayer of the one control the lock.					
Application Number	NOT YET ASSIGNED				
Filing Date	SEPTEMBER 5, 2003				
First Named Inventor	BATTISTA et al				
Group Art Unit	NOT YET ASSIGNED				
Examiner Name	NOT YET ASSIGNED				
Attorney Docket Number	PRD-0039-USA-NP				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
p		CALO, G. et al., "Pharmacological Profile of Nociceptin/Orphanin FQ Receptors" Clinical and Experimental Pharmacology and Physiology (2002), 29, 223-228.	
P		CHALON, S. et al *todoethylspiperone, a New Potential Agent for Exploration of Central Dopamine D ₂ Receptors: Synthesis and Preliminary In Vivo Study* Nucl. Med. Bio. (1990), 17(4), 389-395.	
PO		KIESEWETTER, D. et al., "Syntheses and D ₂ Receptor Affinities of Derivatives of Spiperone Containing Aliphatic Halogens" Appl. Radiat. Isot. (1986), 37(12), 1181-1188.	
10		POULAIN, R. et al., "From Hit to Lead. Analyzing Structure - Profile Relationships" J.Med. Chem. (2001), 44, 3391-3401.	
ps		POULAIN, R. et al., "From Hit to Lead. Combining Two Complementary Methods for Focused Library Design. Application to μ Opiate Ligands" J. Med. Chem. (2001), 44, 3378-3390.	
po		RÖVER S. et al., "High-Affinity, Non-Peptide Agonists for the ORL1 (Orphanin FQ/Nociceptin) Receptor J. Med. Chem. (2000), 43, 1329-1338.	
Oq		SATYAMURTHY, N. et al., "3-(21"F]Fluoroethyl)spiperone, a Potent Dopamine Antagonist Synthesis, Structural Analysis and In-vivo Utilization in Humans* Appl. Radiat. Isot. (1990) 41(2), 113-129.	
			•

Examiner	•	Date	9/./20
Signature	Roeras	Considered	7/1/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SUBMISSION UNDER MPEP 609 D

Application Number 10/656,934

Filing Date September 5, 2003

First Named Inventor Kathleen Battista

Group Art Unit 1625

Examiner Name Not Yet Assigned

Attorney Docket Number PRD-0039-USA-NP

Page 1 of 1

U.S. Patent Document

| U.S. Patent Document | U.S. Patent Document | Pages, Columns, Lines, where relevant passages or relevant figures appear | Pages, Columns (if known) | Pages, Columns (if known

		FOREIG	NPATENT	DOCUME	vits		
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document		Petent Docum		Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁰
	140.						
				+			
							
			<u> </u>				
			1	1 .			
		<u> </u>					
		<u> </u>	 			 	
				·1			
		OTHER PRIOR ART - N	ON PATER	IT LITERATI	RE DOCUME	rts en	
Examiner 's tnitials*	Cite No.1	include name of the author (in C title of the item (book, magazin volume-Issue number(APITOL L e, journal, e), publish	ETTERS), (serial, symp er, city and/	title of the arti posium, catalo for country with	cle (when appropriate), og, etc.), date, page(s), ere published	T ²
ITHUBIS		PCT Search Report dated February 18	, 2004 for F	CT APPLN.	NO PCT/US03	/27956	
							1
							
							+
							

Examiner	Ra	Date Considered	9/1	o 5
Signature				

PTO/SB/08A (03-00)
Approved for use through 10/31/2002 ONB 0551-0031 .
U.S. Patent and Trademant Office U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as nocessary) Sheet 1 of 1

Application Number	10/656,934
Filing Date	September 5, 2003
First Named Inventor	Kathleen Battista
Group Art Unit ·	1625
Examiner Name	Not Yet Assigned
Attorney Docket Number	PRD-0039-USA-NF

U.S. PATENT DOCUMENTS							
Examiner initials	Cite	U.S. Patent Docume	Kind Code ² (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	
		•			<u> </u>	ļ <u> </u>	
						•	
·		· · · · · · · · · · · · · · · · · · ·					
						 	
			i l	•	<u>il</u>		
							
			_		 	ļ 	
			5000	EIGN PATENT DOCUMENTS			

		Foreign Patent Docum		ent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	70
Examiner Initials	Cite No.1	Office ³	Number ⁴ 1	(IndCode ⁶	Applicant of Cited Document mm-dd-yyyy		passages or relevant figures appear	
RP		wo	01 46192	A	Meiji Seika Kaisha LTD.	06-28-2001	with its English Abstract	L
- 		•						
	-							_
				1			·	

Exeminer Signature	Roenat	Date Considered	7/	12/04.

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Emer Office that issued the document, by the two-latter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, a Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Tredemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Party of Reduction A Substitute for form 1449AN OF TRACE

PTC/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

U.S. Patent Document

a conection of information unless it displays	8 Tally UNID CONDOTTIONS CI.
Application Number	10/656,934
Filing Date	September 5, 2003
First Named Inventor	Battista et al.
Group Art Unit	1625
Examiner Name	Rita I. Desai
Attorney Docket Number	PRD-0039

Examiner Initials	Cite No.1	Number		Kind Code ² (if known)	Name of Patentee or Applica of Cited Document	nt	Date of Publication of Cited Docume mm-dd-yyyy	on ent v	Pages, Columns, Li where relevant passa relevant figures app	ges or
W		6,777,42	21	B2	Jordan et al.		8-17-2004			
								\perp		
								\perp	· <u>. </u>	
	<u> </u>						ļ	_		
	ļ						ļ	_		
	<u> </u>	ļ								
	 	ļ					 	_		
	ļ	<u> </u>					<u> </u>	_		
	<u> </u>	<u> </u>						+		
		-								
	<u> </u>	<u> </u>		FOR	EIGN PATENT DOCUMENTS					
	Ī	Foreign	Patent Doc				Date of Publication of Cited Document	Page	s, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴	KindCode ⁵	Name of Patentee or Applicant of Cited Document	'	mm-dd-yyyy	pas	sages or relevant figures appear	T ⁶
. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							•			
						\bot				_
·	<u> </u>	<u></u>	<u>. </u>				<u></u>	<u> </u>		
Examiner				00 =	no Dat		T	Ŷ	1/26/05	

U.S. PATENT DOCUMENTS

Signature | Considered | Consid and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Examiner

Signature

Application Number	10/656,934
Filing Date	September 5, 2003
First Named Inventor	Battista et al.
Group Art Unit	1625
Examiner Name	Rita I. Desai
Attorney Docket Number	PRD-0039

Examiner Initials No.¹ Name of Patentee or Applicant of Cited Document of Cited Document of Cited Document Number (if known)

Ortho-McNeil Pharmaceutical, Inc. 10/909,858

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or or relevant figures Cite Examiner Applicant of Cited Document Initials Office³ Number⁴ KindCode⁵ appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Cite No.1 Examiner Initials*

Date

JAN 2 1 2005 20 JAN 2 1 2005 2005 20 JAN 2 1 2

PTC/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	valid OMB control number.
Application Number	10/656,934
Filing Date	September 5, 2003
First Named Inventor	Battista et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	PRD0039USNP

		U.S. Patent Document				
Examiner Cite Initiats No.1	ľ	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
B		6,113,527	Α	Hoffmann-La Roche Inc.	9-05-2000	
	ļ					
						
	 				<u> </u>	
· .						
	.					
					_	

		Foreign	Patent Docume	int	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴ Ki	indCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Τ*
R		wo	01/96337	A1	Banyu Pharmaceutical Co., Ltd.	6-08-2001		Ŀ
P		wo	03/010168	A1	Banyu Pharmaceutical Co., Ltd.	7-23-2001		
re		wo	02/085355	A1	Euro-Celtique, S.A.	10-31-2002		ļ
	<u> </u>			 				
	<u> </u>	 -						

and the second s		
Examiner Signature	Date Considered	7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB08A (08-00)
Approved for use through 10/31/2002, CMB 0651-0031
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OND

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a vaid CMB compliments.
10/656,934
September 5, 2003
Battista et al.
1625
Rita J. Desal
PRD0039USNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ²
RS		Ronzoni, Silvano et al., "Lead generation and lead optimization approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists," Exp. Opin. Ther. Patents, 2001, (11)4, pp. 525-646	
μ		Zaveri, Nurulain, "Peptide and nonpeptide tigands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents," Life Sciences 73 (2003), pp. 663-678	
Po		Jenck, Francols et al., "A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat," PNAS, April 25, 2000, vol. 97, no. 9, pp. 4938-4953	
Ø.		Thomsen, Christan et al., "(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-trlaza-spiro(4.5)-dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist," British Journal of Pharmacology (2000) 131, 903-908	

Examiner	K D Van	Date	126/26
	100	1000	612010
Signature		Considered	1103/00
Olgitotoro 1			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

i Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.